| Literature DB >> 34156107 |
Davide Schiroli1, Lucia Merolle1, Giuseppe Molinari1, Erminia Di Bartolomeo1, Daniela Seligardi1, Laura Canovi1, Thelma A Pertinhez1,2, Pamela Mancuso3, Paolo Giorgi Rossi3, Roberto Baricchi1, Chiara Marraccini1.
Abstract
BACKGROUND AND OBJECTIVES: The first wave of coronavirus disease-2019 (COVID-19) dramatically affected the Transfusion Medicine Unit of the Azienda Unità Sanitari Locale - Istituto di Ricovero e Cura a Carattere Scientifico (AUSL-IRCCS) di Reggio Emilia, which faced a total rearrangement of the procedures for donors and patients. This study aims to assess the major implications of COVID-19 on our department, focusing on the blood transfusion chain and therapies, in order to support transfusion specialists in seeking efficient ways to face similar future emergencies.Entities:
Keywords: blood collection; donor recruitment; platelet transfusion; transfusion medicine (in general); transfusion therapy
Mesh:
Year: 2021 PMID: 34156107 PMCID: PMC8447465 DOI: 10.1111/vox.13174
Source DB: PubMed Journal: Vox Sang ISSN: 0042-9007 Impact factor: 2.996
FIGURE 1(a) Whole blood–derived RBCs, weekly donations between February and May 2020, and (b) platelets apheresis donations collected in the same period. LD, lockdown; RBCs, red blood cells; PLTs, platelets
Patients transfused and total patients hospitalized by the AUSL‐IRCCS di Reggio Emilia between February and May 2020 (absolute number), compared to the same period of 2017–2019 (mean)
| February–May | Transfused patients | Hospitalized patients | % Transf./Hosp. |
|---|---|---|---|
| 2017–2019 (mean value) | 2920 | 15,771 | 18.5 |
| 2020 COVID negative | 2373 | 10,520 | 22.5 |
| 2020 COVID positive | 161 | 1720 | 9.4 |
FIGURE 2RBCs transfusions in 2020 (black lines), compared with the same period of the previous triennium. (a) Patients transfused with RBCs (left panel) and RBCs units transfused (right panel); (b) patients and units transfused for orthopaedics surgery; (c) patients and units transfused for cardiovascular surgery and (d) patients and units transfused for cancer other than haematological. *p ≤ 0.05, **p ≤ 0.001 and ***p ≤ 0.0001. RBCs, red blood cells
FIGURE 3(a) Patients transfused with PLTs (left panel) and PLTs units transfused in 2020, compared to the same period of 2019 and (b) buffycoat‐derived (pool) and apheresis‐derived (PLT apheresis) PLTs units transfused between February and May 2020. *p ≤ 0.05, **p ≤ 0.001 and ***p ≤ 0.0001. LD, lockdown; PLT, platelet
FIGURE 4Patients and units transfused for onco‐haematological diseases: (a) RBCs and (b) PLTs. *p ≤ 0.05, **p ≤ 0.001. LD, lockdown; PLTs, platelets; RBCs, red blood cells
FIGURE 5Transfusion medicine and immune‐haematology clinical practice procedures performed for: (a) inpatients coming from other wards; (b) outpatients and (c) medical consultations for outpatients. Black line indicates 2020 procedures, while grey line indicates 2019 procedures. LD, lockdown; LDL, low density lipoprotein; PLS, plasma